KIORA PHARMACEUTICALS INC 8K

Kiora Pharmaceuticals reported Q1 2026 results, updated progress on its KIO-301 and KIO-104 retinal disease trials, and noted a strengthened balance sheet and cash runway into late 2028 following a strategic equity financing.

On May 8, 2026, Kiora Pharmaceuticals, Inc. reported its financial results for the first quarter ended March 31, 2026, highlighting active enrollment and site expansion for its Phase 2 ABACUS-2 trial of KIO-301 for retinitis pigmentosa, publication of ABACUS-1 results in Nature Medicine, continued progress and a pending safety review in its Phase 2 KLARITY study of KIO-104 for inflammatory retinal disease, and disclosure that it has an operational cash runway into late 2028 supported by $13.9 million in cash and short-term investments at quarter end plus a subsequent $5 million strategic equity financing led by Perceptive Advisors and ADAR1, while reporting a quarterly net loss of approximately $2.4 million.

Filing Facts

CIK

1372514

Ticker

-

Form

8K

Source Type

sec

Accession

0001372514-26-000048

Alert Tier

6